EUSA Finds Japanese Partner For Lead Product In Generics-turned-innovator Ohara
This article was originally published in PharmAsia News
TOKYO - In-licensing firm EUSA Pharma established its first partnership in Japan, behind similar deals in South Korea and China, for its acute lymphoblastic leukemia treatment Erwinase (erwinia L-asparaginase)
You may also be interested in...
Eusa hopes the approval will help cement its efforts in the U.S., where it has been trying to build a strong presence for several years.
SHANGHAI - NovaMed Pharmaceuticals announced July 10 it has reached agreements with U.S.-based Iroko and U.K. firm EUSA Pharma to in-license Iroko's cardiovascular drugAggrastat (tirofiban) and EUSA's oncology drug Erwinase (crisantaspase)
Buyout positions U.K. drug maker to take on new licensing deals on both sides of the Atlantic; oncology filing planned within 12 months, EUSA tells the DAILY.